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ABSTRACT
Objective: Standard pharmacotherapy for patients with gastroesophageal
reﬂux disease (GERD) includes treatment with proton pump inhibitors
(PPIs). This study examined the effect of GERD patients’ compliance with
PPI therapy on health-care resource utilization and costs.
Methods: This was a retrospective study of more than 25 million
managed care lives in the United States from January 2000 through
February 2005. Administrative claims data were obtained from the
National Managed Care Benchmarks database, developed by Integrated
Health Care Information Solutions. GERD-diagnosed patients who had
at least two PPI dispensings were extracted and grouped into two
treatment categories based on their PPI medication possession ratio
(MPR): compliant (MPR > 0.8) and noncompliant. A regression-based
difference-in-differences approach was used to estimate the effect of
compliance on the frequency and costs of inpatient and outpatient visits
and pharmacy costs. Statistical controls included health plan type,
patient age, baseline use of nonsteroidal antiinﬂammatory drugs, and
comorbidities.
Results: Of the total 41,837 patients studied, 68% were compliant. On an
annual, per-patient basis, PPI compliance resulted in 0.47 fewer outpatient
visits (P = 0.040), 0.03 fewer inpatient visits (P = 0.015), and 0.47 fewer
hospitalization days (P = 0.001) from the pre-PPI use period, compared to
noncompliance. PPI therapy increased pharmacy costs for both groups,
but the total annual health-care costs were reduced for both groups.
Compliant patients experienced a greater decline in total cost from the
pre-PPI period compared to noncompliant patients (declines of $3261 vs.
$2406 per patient per year, P = 0.012).
Conclusions: Both health-care resource use and costs were reduced after
initiation of PPI therapy. Additional reductions from the pre-PPI period
were further observed by compliance with PPI therapy.
Keywords: compliance, costs, GERD, PPI, resource utilization.
Introduction
Gastroesophageal reﬂux disease (GERD) is a common, chronic
disorder. In the United States, approximately 20% of people aged
25 to 74 years reported weekly or more frequent occurrence of
heartburn and/or acid regurgitation [1]. GERD is characterized
by symptoms including frequent heartburn and acid regurgita-
tion which may lead to inﬂammation of the esophagus. This can
lead to esophageal erosions, which are observed in approxi-
mately 28% of GERD patients [2]. The aggregate direct cost of
treating GERD makes it the most costly gastrointestinal disease
in the United States. It is estimated that in 1998 GERD was
associated with direct medical and drug costs in excess of $10
billion (2000 US dollars) [3].
The mainstay of therapy for GERD is acid suppressive
therapy, with proton pump inhibitors (PPIs) being more effective
in controlling gastric acid than other available agents [4].
Adverse effects of PPIs are usually minor, infrequent, well-
characterized, and manageable.
One factor that can inﬂuence both health outcomes and cost
is the extent to which patients comply with their prescribed
therapy. This has been conﬁrmed by researchers in a number of
disease areas, such as the use of statins for coronary heart disease
and antipsychotics for schizophrenia [5,6]. In general, the effects
and importance of compliance in evaluating various management
strategies have been overlooked [7,8]. To the best of our knowl-
edge, only one study has examined the effects of PPI therapy
compliance in patients with GERD. Hall et al. [9] found that for
several PPIs, compliance with therapy increased pharmacy costs
by 43% (P < 0.001) and increased GERD-related total costs by
34% (P < 0.001), relative to patients who were noncompliant.
The authors concluded that PPI compliance did not decrease
GERD-related costs. That study limited its cost evaluation to
services with a primary diagnosis of GERD, so any changes in the
use of health-care services not speciﬁcally recorded with a GERD
diagnosis were not captured.
The present study examined the effect of PPI therapy compli-
ance on overall health-care resource utilization and costs in a
managed care population. The costs were calculated from a
private insurance payer’s perspective. Better understanding this
relationship may provide an opportunity to improve GERD man-
agement and reduce health-care resource utilization and costs.
Methods
Data Source
This study used administrative claims data from the National
Managed Care Benchmarks database, developed by Integrated
Health Care Information Solutions (IHCIS). This database
includes complete medical history on more than 25 million
managed care lives in more than 30 health plans covering all
regions of the United States. Data from all contributing plans go
through a series of evaluation and reconciliation steps to mini-
mize the presence of errors. In particular, each data ﬁeld goes
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through a systematic evaluation and cleaning process to ensure
that complete and appropriate values are recorded for each data
element. Data elements include patient demographics, enroll-
ment records, inpatient and outpatient diagnostics and proce-
dures, and outpatient pharmacy dispensing claims. Data from
January 2000 through February 2005 were extracted.
Patients
This retrospective cohort study of GERD patients compared
compliant to noncompliant PPI users. PPIs included in this study
were the generic and branded versions of esomeprazole, lanso-
prazole, omeprazole, pantoprazole, and rabeprazole. To be
included in the study, patients had to be continuously enrolled in
a health plan, be 18 years of age or older at the time a PPI was
ﬁrst dispensed, have at least two insurance claims with a GERD
diagnosis to conﬁrm the diagnosis and to avoid coding errors
from patients with one claim (International Classiﬁcation of
Diseases, Ninth Revision [ICD-9] diagnosis code 530.1, 530.81,
787.1), have at least 90 days of eligibility before their ﬁrst GERD
claim (GERD index date), and be PPI users with the date of the
ﬁrst PPI dispensing (PPI index date) at least 30 days after the ﬁrst
GERD claim and 30 days before the end of eligibility. Patients
had to have a continuous period of PPI therapy in which PPIs
were dispensed multiple times. Speciﬁcally, a patient 1) had to
have at least one PPI episode, which is deﬁned as a continuous
period of PPI therapy with no interruption of more than 56 days
in supply; and 2) had to have at least two PPI dispensings within
an episode, which enables measurement of patient compliance.
For example, a patient who is ﬁrst dispensed a 30-day pill supply
and obtains a reﬁll within 86 days of the ﬁrst dispensing would
satisfy these two criteria.
Compliance for each patient in the study was measured using
the medication possession ratio (MPR), which is deﬁned by this
equation:
MPR
Days of PPI supply
Days between first and last refills
=
+
days of supply of last refill
The numerator of this ratio is the total days of PPI supply
prescribed, including all reﬁlls. The denominator captures the
duration of time that a patient is supposed to be treated; it is
calculated as the number of days between the ﬁrst and last reﬁlls,
plus the number of days of supply for the last reﬁll [10]. If a
patient had more than one PPI episode, the MPR was calculated
as the sum of the pill supply days in each episode, divided by
the sum of the durations in each episode. A patient with an
MPR > 0.8 was deﬁned as compliant; this cutoff value is used
widely in the literature [11,12].
Baseline Characteristics
Basic demographic information (age, sex) and health plan type
(e.g., health maintenance organization [HMO], point-of-service,
preferred provider organization [PPO]) were compared between
the PPI noncompliant and compliant groups. Also extracted were
data for use as markers of GERD severity, including cough,
asthma, sleeplessness, chronic pain, dyspepsia, and dysphagia
[13]. As an indicator of general health state, the Charlson comor-
bidity index was also calculated [14]. The use of nonsteroidal
antiinﬂammatory drugs (NSAIDs) and Cox-2 inhibitors, which
have been studied for their association with gastrointestinal
adverse effects, was also assessed [15,16].
Outcome Measures
The average annualized numbers of outpatient visits, inpatient
visits, and hospitalization days were calculated and compared
between the two study groups. Multiple outpatient visits on the
same day were considered as a single visit. Total health-care costs
were categorized as medical (i.e., outpatient and inpatient) and
pharmacy (i.e., prescription drugs), and were calculated on an
average annualized cost basis. The reported costs are those
incurred by third-party payers and therefore did not include costs
incurred by patients (e.g., copayments and deductibles).
Statistical Analysis
A regression-based difference-in-differences approach was used
to estimate the effect of compliance with PPI therapy on health-
care resource utilization and costs. The pre-PPI period was
deﬁned as starting with the ﬁrst GERD claim until the day before
the initiation of PPI therapy. The post-PPI period was deﬁned as
starting with the initiation of PPI therapy until the end of eligi-
bility or the deﬁned study end date (February 28, 2005), which-
ever occurred ﬁrst. Within each patient group, the incremental
effect of PPI therapy was calculated as the difference between the
post- and pre-PPI periods for each outcome measure. Those
incremental effects of PPI treatment were then compared between
the compliant and noncompliant groups to estimate the effect of
compliance.
Univariate and multivariate linear regression analyses were
performed. The multivariate analyses controlled for potential
confounding factors, including health plan type, PPI index year,
age, sex, length of time since the ﬁrst GERD diagnosis, baseline
use of Cox-2 inhibitors and NSAIDs, and the Charlson comor-
bidity index. To assess the robustness of the results, sensitivity
analyses excluding potentially endogenous covariates (i.e., health
plan type, length of time since the ﬁrst GERD diagnosis, baseline
use of Cox-2 inhibitors and NSAIDs, and the Charlson comor-
bidity index) and a Variance Inﬂation Factor (VIF) test were
performed.
All statistical analyses were performed using the SAS software
version 9.1 (SAS Institute Inc., Cary, NC, USA). To test for
statistically signiﬁcant differences between two groups, Student’s
t-test was used with continuous outcome variables following a
normal distribution, the nonparametric Wilcoxon sum-rank test
was used for continuous variables with strictly positive values,
and the Poisson test was used for count variables. A two-sided
alpha level of 0.05 was used.
Results
Study Groups and Baseline Characteristics
Of the 41,837 patients who met the inclusion criteria, 28,321
and 13,516 were respectively identiﬁed as PPI compliant and
noncompliant patients. Table 1 shows the baseline characteristics
of the sample population. Compliant patients were older than
noncompliant patients (mean age: 50.5 vs. 47.2 years;
P < 0.001). Patients were enrolled in a variety of health plan
types, though most were in HMOs and PPOs. At baseline, the
compliant and noncompliant groups did not statistically differ
with respect to some GERD-related symptoms, such as cough,
asthma, and dysphagia, but the compliant group had a greater
prevalence of sleeplessness and chronic pain. Compliant patients
had a higher utilization of NSAID (6.2% vs. 5.7%, P = 0.041)
and Cox-2 inhibitor drugs (5.3% vs. 3.8%, P < 0.001), and had
slightly more comorbidities (Charlson comorbidity index: 0.5 vs.
0.4; P < 0.001) than the noncompliant patients.
Univariate Analysis
Table 2 shows the average annualized number of visits and
lengths of hospital stays of the compliant and noncompliant
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groups for the pre- and post-PPI periods as well as the incremen-
tal difference between the two periods for each group. For both
compliant and noncompliant groups, visits and hospital stays
decreased in the post-PPI period compared to the pre-PPI period.
The relative decrease in outpatient visits between the pre-PPI and
post-PPI periods was similar between compliant and noncompli-
ant groups (6.59 vs. 6.65 fewer visits per year, P = 0.780). Nev-
ertheless, the compliant group experienced signiﬁcantly greater
relative declines in the number of emergency room (ER) visits
(0.21 vs. 0.16 fewer visits per year, P = 0.024), inpatient visits
(0.12 vs. 0.08 fewer visits per year, P = 0.003), and hospital
lengths of stay (0.71 vs. 0.17 fewer days per year, P < 0.001).
Table 3 shows similar analyses but evaluates the impacts on
health-care costs. Pharmacy costs increased for both compliant
and noncompliant groups from pre- to post-PPI periods, and the
increase was $412 larger for compliant than for noncompliant
patients ($680 increase vs. $269 increase; P < 0.001). With
respect to medical costs, both patient groups experienced a
decline following initiation of PPI therapy. Medical costs in the
post-PPI period decreased $1124 more for the compliant patients
than for noncompliant patients ($3895 decrease vs. $2771
decrease; P < 0.001). The cost decrease in the medical service
components offset the cost increase in the prescription drugs, and
the net effect was that total annual health-care costs decreased by
$3215 for compliant patients and by $2503 for noncompliant
patients; the larger cost reduction observed among compliant
patients was statistically signiﬁcant (P = 0.022).
Multivariate Analysis
Table 4 reports the incremental number of visits and costs
adjusted for baseline differences between the compliant and non-
compliant groups. Consistent with the univariate ﬁndings, com-
pliant patients experienced larger decreases from pre- to post-PPI
periods than noncompliant patients with respect to outpatient
visits (6.76 decrease vs. 6.29 decrease, P = 0.040), inpatient visits
(0.11 decrease vs. 0.08 decrease, P = 0.015), and hospital lengths
of stay (0.69 decrease vs. 0.22 decrease, P = 0.001). Both patient
groups experienced reductions in annual medical costs following
commencement of PPI therapy, but the reduction was greater by




(n = 28,321) P-value
Age, mean (SD) 47.2 (12.7) 50.5 (12.7) <0.0001
Female, n (%) 7,521 (55.6) 15,871 (56.0) 0.4472
Health plan type, n (%) <0.0001
HMO 5,321 (39.4) 11,299 (39.9)
IND 749 (5.5) 2,155 (7.6)
POS 1,310 (9.7) 3,144 (11.1)
PPO 5,893 (43.6) 11,209 (39.6)
Other 243 (1.8) 514 (1.8)
GERD-related comorbidities, n (%)
Cough 686 (5.1) 1,515 (5.3) 0.2405
Asthma 1,088 (8.0) 2,322 (8.2) 0.6021
Sleeplessness 568 (4.2) 1,364 (4.8) 0.0052
Chronic pain 1,933 (14.3) 4,507 (15.9) <0.0001
Dyspepsia 804 (5.9) 1,543 (5.4) 0.0376
Dysphagia 1,295 (9.6) 2,841 (10.0) 0.1491
NSAID utilization, n (%) 772 (5.7) 1,762 (6.2) 0.0409
COX-2 utilization, n (%) 513 (3.8) 1,496 (5.3) <0.0001
Charlson comorbidity index, Mean (SD) 0.4 (0.9) 0.5 (1.1) <0.0001
Wilcoxon sum-rank test P-values were reported for continuous variables with strictly positive values; chi-square P-values were reported for categorical variables.
Cox-2, cyclooxygenase; GERD, gastroesophageal reﬂux disease; HMO, health maintenance organization; IND, indemnity plan; NSAID, nonsteroidal anti-inﬂammatory drug; POS, point-of-service
plan; PPO, preferred provider organization; SD, standard deviation.




(n = 28,321) P-value
Pre-PPI period, mean (SD)
Outpatient visits per year 24.39 (22.69) 26.90 (25.56) <0.0001
ER visits per year 0.68 (2.24) 0.68 (2.26) 0.2691
Inpatient visits per year 0.26 (1.21) 0.31 (1.38) <0.0001
Hospital length of stay, days per year 1.49 (9.93) 2.09 (14.02) <0.0001
Post-PPI period, mean (SD)
Outpatient visits per year 17.74 (19.48) 20.31 (21.88) <0.0001
ER visits per year 0.52 (1.42) 0.46 (1.34) <0.0001
Inpatient visits per year 0.19 (0.72) 0.20 (0.78) 0.0053
Hospital length of stay, days per year 1.32 (7.61) 1.38 (7.92) <0.0001
Incremental from pre- to post-PPI period, mean (SD)
Outpatient visits per year -6.65 (20.92) -6.59 (23.40) 0.7801
ER visits per year -0.16 (2.23) -0.21 (2.23) 0.0238
Inpatient visits per year -0.08 (1.26) -0.12 (1.41) 0.0031
Hospital length of stay, days per year -0.17 (10.84) -0.71 (14.72) <0.0001
Poisson P-values were reported for count variables; Student’s t-test P-values are reported for incremental variables.
ER, emergency room; PPI, proton pump inhibitor; SD, standard deviation.
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$1204 for compliant patients ($3921 decrease vs. $2717 decrease;
P < 0.001). Pharmacy costs in the post-PPI period increased for
both compliant and noncompliant patients, but compliant
patients had a $349 higher increase ($660 increase vs. $311
increase; P < 0.001). The net impact of PPI therapy on total
annual health-care costs was a reduction of $3261 for compliant
patients and $2406 for noncompliant patients; the difference is the
effect of compliance, which corresponds to an additional reduc-
tion of $855 per year (P = 0.012). Adjustment for the covariates
increased the estimate of the effect of compliance ($855 vs. $712)
and increased the statistical signiﬁcance of the estimate slightly
(P-values of 0.012 vs. 0.022). Exclusion of covariates showed that
the results were robust to the model speciﬁcation. For instance, the
impact of PPI compliance on total annual health-care costs ranged
from $776 to $937 across the different speciﬁcations. Also the VIF
test showed variance inﬂation factors of less than two for all
variables, which implies that no material collinearity of covariates
was present.
Discussion
The high prevalence of GERD and the high aggregate cost asso-
ciated with this disease make the management of GERD a high
priority for patients, health-care providers, and third-party
payers. Signiﬁcant literature exists on the pharmacology of PPIs,
which have emerged as a leading choice for controlling GERD
[6]. Studies of other diseases and therapies have shown that
higher compliance rates can lead to beneﬁcial outcomes with
respect to health and/or cost [7–10]. This retrospective cohort
study adds to this literature by examining the relationship
between PPI compliance and health-care resource utilization and
cost.
Patients in this study were observed to experience reductions
in health-care utilization following initiation of PPI therapy,
which is consistent with existing literature on the beneﬁcial
effects of PPI therapy [4]. This study was designed to measure the
incremental impact of compliance versus noncompliance. This
study has found that a sizeable fraction (32%) of GERD patients
who take PPIs were noncompliant and that patients who were
compliant with PPI therapy experienced a signiﬁcantly greater
reduction in the number of outpatient, ER, and inpatient visits.
Compliant patients experienced approximately a threefold
reduction in the number of hospitalization days per year (0.69
decrease vs. 0.22 decrease, P = 0.001). The inpatient utilization
reduction accounted for 67% of the overall medical cost reduc-
tion associated with compliance with PPI therapies.
This study also ﬁnds that pharmacy costs increased more for
compliant patients than for noncompliant patients, as expected,




(n = 28,321) P-value
Pre-PPI period, mean (SD)
Outpatient 8,006 (14,470) 9,188 (16,299) <0.0001
Inpatient 2,340 (16,176) 3,452 (23,885) <0.0001
Total, medical 10,346 (25,049) 12,640 (33,719) <0.0001
Pharmacy 1,653 (2,097) 2,209 (2,679) <0.0001
Total, medical and pharmacy 11,999 (25,605) 14,849 (34,302) <0.0001
Post-PPI period, mean (SD)
Outpatient 5,458 (11,665) 6,427 (16,985) <0.0001
Inpatient 2,116 (12,043) 2,318 (13,543) 0.9138
Total, medical 7,575 (20,143) 8,745 (25,449) <0.0001
Pharmacy 1,922 (2,368) 2,889 (3,067) <0.0001
Total, medical and pharmacy 9,497 (21,001) 11,634 (26,393) <0.0001
Incremental annualized costs, mean (SD)
Outpatient -2,548 (14,316) -2,761 (18,551) 0.1976
Inpatient -224 (18,410) -1,135 (25,143) <0.0001
Total, medical -2,771 (26,286) -3,895 (34,971) 0.0003
Pharmacy 269 (1,900) 680 (2,444) <0.0001
Total, medical and pharmacy -2,503 (26,589) -3,215 (35,282) 0.0217
Wilcoxon sum-rank test P-values were reported for count variables; Student’s t-test P-values are reported for incremental variables.
PPI, proton pump inhibitor; SD, standard deviation.
Table 4 Adjusted* annual incremental number of visits and costs: multivariate analysis
Noncompliant Compliant Difference† P-value
Incremental annualized resource utilization, mean (SD)
Outpatient visits -6.29 -6.76 -0.47 0.0396
ER visits -0.15 -0.22 -0.07 0.0044
Inpatient visits -0.08 -0.11 -0.03 0.0151
Hospital length of stay (days) -0.22 -0.69 -0.47 0.0010
Incremental annualized costs ($), mean (SD)
Outpatient -2425 -2819 -395 0.0281
Inpatient -292 -1102 -810 0.0009
Total, medical -2717 -3921 -1204 0.0004
Pharmacy 311 660 349 <0.0001
Total, medical and pharmacy -2406 -3261 -855 0.0123
*Covariates included in the model are: compliance dummy,health plan type, PPI index year, age, sex, time between ﬁrst GERD diagnostic and PPI initiation, dummies for the use of Cox-2 inhibitors
and NSAIDs at baseline, Charlson comorbidity index.
†Compliant group minus noncompliant group.
ER, emergency room; SD, standard deviation.
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while medical costs declined more for compliant patients than for
noncompliant patients. Because medical costs formed the bulk of
total health-care costs, the net effect of PPI therapy was that total
costs declined for both patient groups. Moreover, compliant
patients experience a greater relative decrease in total costs than
noncompliant patients. This study estimated the total annual
cost-savings associated with compliance at $855 per patient. This
estimate was based on a multivariate regression model that
explicitly controls for a number of potentially confounding
factors.
A simple calculation can put into perspective the magnitude
of this compliance effect. Using the results shown in Table 3, the
average GERD patient was estimated to incur $10,944 (weighted
average) in total annual costs after initiation of PPI therapy. This
study estimates that compliance induced a decrease of $855 in
total annual costs. This implies that a noncompliant PPI user that
would become compliant would experience an 8% (855/10,944)
reduction in total cost. Considering the high prevalence of GERD
and the substantial fraction of PPI users that are noncompliant,
the aggregate cost-savings associated with greater compliance
may be substantial at a system level.
These results on the cost-saving effect of PPI therapy compli-
ance appear inconsistent with the ﬁndings of Hall et al., which
reported that PPI compliance increased GERD-related total costs
by 34%, compared to noncompliance [11]. Nevertheless, that
study did not take into account the possibility that PPIs may also
have other beneﬁts, such as reducing the adverse gastric side
effects that may accompany use of NSAIDs [17]. Such effects may
not be recorded with a GERD diagnosis and therefore would not
be considered in that study. In contrast, the present study made
no limitation on the types of medical costs considered. Moreover,
consideration of all-cause medical costs is appropriate because
GERD is associated with a suite of symptoms (e.g., asthma,
cough, sleeplessness), and to the extent that medical costs are not
attributed directly to GERD, evaluation of the effects of therapy
may be understated.
This study has several limitations. First, it does not evaluate
the causes of noncompliance. Possible reasons include adverse
side effects, patients who may be self-regulating their dosage after
initially achieving control of GERD, poorly educating patients
about the need for their PPI therapy, as well as inattentive patient
behavior. Noncompliance may also tend to occur with patients
with less severe cases of GERD. Although this study has con-
trolled for severity in estimating the effect of compliance by
including a Charlson comorbidity index in the multivariate
regression models, it cannot ascertain whether this or other
factors are the primary causes of noncompliance. Identifying the
reasons for noncompliance would enhance the design of strate-
gies to improve compliance.
Second, this study relies on administrative claims data. In
some cases, administrative claims provide only proxies for the
information ultimately sought. For example, regular dispensings
that match the days of pill supply indicate compliance, but it is
impossible to know from claims data that the patient actually
took the medication as directed by the physician. A drug claim
indicates the fact that a prescription has been ﬁlled but is not
equal to patient ingestion. Therefore, the MPR method using
pharmacy dispensing claims can be considered as only a surro-
gate marker for patient compliance. Additionally, while the mul-
tivariate analysis indirectly controlled for GERD severity
through the length of time since the ﬁrst GERD diagnosis and the
Charlson comorbidity index (the assumption being that the more
severe the GERD is, the more complications there are), such
measures are only approximations for GERD severity. As a
result, this study is limited in its ability to examine whether the
effect of compliance varies across GERD severity level. Use of
claims data, nevertheless, offers a valuable avenue for analysis,
and future research should explore the use of more detailed
clinical data. In addition, administrative claims data can be
subject to errors in coding. Nevertheless, there is no reason to
believe that these inherent limitations of the claims data have a
differential impact on the compliant and noncompliant groups.
Third, not all costs have been considered in this study. IHCIS
cost information includes only the portion incurred by the third-
party payers; it also is standardized across health plans and
therefore does not reﬂect the actual amounts paid by the various
payers. Other cost items, such as patient copayments and deduct-
ibles, indirect productivity losses, transportation and time oppor-
tunity costs, and over-the-counter drug costs, are not included in
this study. Such cost items may have positive or negative effects
on the observed difference in cost reduction between the compli-
ant and noncompliant groups.
Fourth, this study does not include a dynamic aspect of the
cost-savings observed. Indeed, an interesting analysis would have
been to see how the cost-savings associated with compliance
might have been compounded over time; this is a topic for future
research.
Fifth, although various confounding effects are controlled for
to isolate the cost reductions only due to compliance, it is pos-
sible that some of the confounders used may not have captured
completely the aspects intended to be controlled. Indeed, ele-
ments such as GERD severity, health insurance status, and copay-
ments may not be perfectly captured by the corresponding
variables used in the multivariate regressions. Moreover, this
study does not control for additional confounding effects because
of potential differences in lifestyle characteristics, which are not
available in the IHCIS data.
Conclusion
This study ﬁnds that PPI therapy for GERD patients reduces
health-care resource utilization and cost, taking into account
both pharmacy and medical costs, and that this reduction is
greater for compliant patients. Because a sizeable fraction of
patients using PPI therapy are noncompliant, this suggests that
opportunities exist to achieve reductions in health-care resource
utilization and costs through more effective management of
GERD and better compliance with treatment.
Source of ﬁnancial support: This study was funded by AstraZeneca LP.
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